Австралія - англійська - Department of Health (Therapeutic Goods Administration)

solasta life pty ltd -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

solasta life pty ltd -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

solasta life pty ltd -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

auscan medbio pty limited - ct772 - severe acute respiratory syndrome-associated coronavirus ivds - rapid tests intended for use at the point-of-care to detect the presence of, or exposure to, sars-cov-2 in relevant specimen samples.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - zoledronic acid monohydrate, quantity: 5.33 mg (equivalent: zoledronic acid, qty 5 mg) - injection, solution - excipient ingredients: mannitol; sodium citrate dihydrate; water for injections - - treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures. - treatment of osteoporosis in patients over 50 years of age with a history of at least one low trauma hip fracture, to reduce the incidence of further fractures. - to increase bone mineral density in men with osteoporosis. - to increase bone mineral density in patients with osteoporosis associated with long term glucocorticoid use. - to prevent glucocorticiod-induced bone mineral density loss. - treatment of paget's disease of bone.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - zoledronic acid monohydrate -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - zoledronic acid monohydrate, quantity: 0.0533 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; water for injections; mannitol - ? treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures. ? treatment of osteoporosis in patients over 50 years of age with a history of at least one low trauma hip fracture, to reduce the incidence of further fractures. ? to increase bone mineral density in men with osteoporosis. ? to increase bone mineral density in patients with osteoporosis associated with long term glucocorticoid use. ? to prevent glucocorticoid-induced bone mineral density loss. ? treatment of paget?s disease of bone.

ПАР - англійська - South African Health Products Regulatory Authority (SAHPRA)

sandoz south africa (pty) ltd - infusion (parenteral) - see ingredients - each 100,0 ml solution contains zoledronate trisodium 5,0 mg

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

scigen australia pty ltd - zoledronic acid, quantity: 4 mg (equivalent: zoledronic acid monohydrate, qty 4.264 mg) - injection, solution - excipient ingredients: water for injections; mannitol; nitrogen; sodium citrate dihydrate - prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone. treatment of tumour-induced hypercalcaemia.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

scigen australia pty ltd - zoledronic acid, quantity: 4 mg (equivalent: zoledronic acid monohydrate, qty 4.264 mg) - injection, concentrated - excipient ingredients: mannitol; sodium citrate dihydrate; water for injections; nitrogen - prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone. treatment of tumor-induced hypercalcaemia.